MBX Biosciences (MBX) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Precigen (PGEN) over the past year, gaining 245.2% versus a gain of 127.8%. Precigen is the larger company by market cap ($2.70 billion vs $2.49 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | PGEN |
|---|---|---|
| Share price | $51.70 | $7.56 |
| Market cap | $2.49B | $2.70B |
| 1-day change | -5.21% | +0.20% |
| YTD return | +72.92% | +80.38% |
| 1-year return | +245.19% | +127.79% |
| 5-year return | — | +62.15% |
| EPS (TTM) | $-2.37 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | $-87.00M | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $72.64 | $8.98 |
| 52-week low | $12.94 | $2.99 |
| Distance from 52-week high | -28.83% | -15.87% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +82.40% | +80.68% |
| Average volume | 539.34K | 5.02M |
| Shares outstanding | 48.16M | 358.04M |
| Employees | 63 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed PGEN by 117.4 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
MBX vs PGEN FAQ
Which is bigger, MBX Biosciences or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.70B compared with $2.49B for MBX Biosciences (MBX).
Which stock has performed better over the past year, MBX or PGEN?
MBX returned +245.19% over the past 12 months, compared with +127.79% for PGEN (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.